A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
Status:
RECRUITING
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This study is a prospective, multicenter, open-label, single-arm clinical trial evaluating the safety and efficacy of the ZRMT (Zanubrutinib-Rituximab-Methotrexate-Temozolomide) regimen in the treatment of primary central nervous system lymphoma (PCNSL) with diffuse large B-cell lymphoma.
This study includes an induction phase for PCNSL ± ASCT and a sequential maintenance phase.
Phase:
NA
Details
Lead Sponsor:
Huai'an First People's Hospital
Collaborators:
Affiliated Hospital of Nantong University Northern Jiangsu People's Hospital The Affiliated Hospital of Xuzhou Medical University The First People's Hospital of Changzhou